Misplaced Pages

Sovateltide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Sovateltide
Clinical data
Trade namesTyvalzi
Other namesIRL-1620; PMZ-1620
Legal status
Legal status
  • Rx in India
Identifiers
IUPAC name
  • Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC86H117N17O27
Molar mass1820.974 g·mol
3D model (JSmol)
SMILES
  • CC(C)(C(=O)N((C)CC)C(=O)N(CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)(CC(=O)O)NC(=O)(CC(C)C)NC(=O)(CC3=CNC=N3)NC(=O)(C)NC(=O)(CC4=CC=CC=C4)NC(=O)(CC5=CC=C(C=C5)O)NC(=O)(C(C)C)NC(=O)(C)NC(=O)(CCC(=O)O)NC(=O)(CCC(=O)O)NC(=O)(CC(=O)O)NC(=O)CCC(=O)O
InChI
  • InChI=1S/C86H117N17O27/c1-11-44(7)71(84(127)100-63(86(129)130)35-50-39-88-54-21-17-16-20-53(50)54)103-85(128)72(45(8)12-2)102-82(125)62(38-69(114)115)98-78(121)57(32-42(3)4)96-80(123)60(36-51-40-87-41-89-51)95-73(116)46(9)91-77(120)58(33-48-18-14-13-15-19-48)97-79(122)59(34-49-22-24-52(104)25-23-49)99-83(126)70(43(5)6)101-74(117)47(10)90-75(118)55(26-29-65(106)107)93-76(119)56(27-30-66(108)109)94-81(124)61(37-68(112)113)92-64(105)28-31-67(110)111/h13-25,39-47,55-63,70-72,88,104H,11-12,26-38H2,1-10H3,(H,87,89)(H,90,118)(H,91,120)(H,92,105)(H,93,119)(H,94,124)(H,95,116)(H,96,123)(H,97,122)(H,98,121)(H,99,126)(H,100,127)(H,101,117)(H,102,125)(H,103,128)(H,106,107)(H,108,109)(H,110,111)(H,112,113)(H,114,115)(H,129,130)/t44-,45-,46-,47-,55-,56-,57-,58-,59-,60-,61-,62-,63-,70-,71-,72-/m0/s1
  • Key:DXPHNGAMYPPTBJ-TZMIJSMNSA-N

Sovateltide (development names IRL-1620 and PMZ-1620, sold in India under the brand name Tyvalzi) is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz. Sovateltide stimulates neural progenitor cells in the brain and promotes neurovascular remodeling by forming new neurons (neurogenesis) and blood vessels (angiogenesis). Sovateltide also protects neural mitochondria and enhances their biogenesis.

References

  1. Gulati, Anil; Agrawal, Nilesh; Vibha, Deepti; Misra, U. K.; Paul, Birinder; Jain, Dinesh; Pandian, Jeyaraj; Borgohain, Rupam (January 2021). "Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke". CNS Drugs. 35 (1): 85–104. doi:10.1007/s40263-020-00783-9. ISSN 1179-1934. PMC 7872992. PMID 33428177.
  2. ^ Keam, Susan J. (September 2023). "Sovateltide: First Approval". Drugs. 83 (13): 1239–1244. doi:10.1007/s40265-023-01922-4. ISSN 1179-1950. PMID 37486545. S2CID 260114948.
  3. Ranjan, Amaresh K.; Gulati, Anil (2022-03-15). "Sovateltide Mediated Endothelin B Receptors Agonism and Curbing Neurological Disorders". International Journal of Molecular Sciences. 23 (6): 3146. doi:10.3390/ijms23063146. ISSN 1422-0067. PMC 8955091. PMID 35328566.
  4. Ranjan, Amaresh K.; Briyal, Seema; Khandekar, Divya; Gulati, Anil (September 2020). "Sovateltide (IRL-1620) affects neuronal progenitors and prevents cerebral tissue damage after ischemic stroke". Canadian Journal of Physiology and Pharmacology. 98 (9): 659–666. doi:10.1139/cjpp-2020-0164. ISSN 0008-4212. PMID 32574518.
  5. Ranjan, Amaresh K.; Briyal, Seema; Gulati, Anil (2020-07-29). "Sovateltide (IRL-1620) activates neuronal differentiation and prevents mitochondrial dysfunction in adult mammalian brains following stroke". Scientific Reports. 10 (1): 12737. Bibcode:2020NatSR..1012737R. doi:10.1038/s41598-020-69673-w. ISSN 2045-2322. PMC 7391684. PMID 32728189.
Categories: